Aminoacylase-2 Deficiency

Aminoacylase-2 deficiency—the condition better known today as Canavan disease (aspartoacylase deficiency) is a rare, inherited brain disease. Doctors now call it Canavan disease. It happens when the ASPA gene does not work correctly. The ASPA gene makes an enzyme called aspartoacylase, which is also called aminoacylase-2. This enzyme normally breaks down a natural brain chemical named N-acetyl-L-aspartic acid (NAA). When the enzyme is missing or weak, NAA builds up to very high levels in the brain. This build-up harms the white matter (the myelin) that helps brain cells send signals. Because of this, babies develop slowly, lose skills, and often have large heads, weak muscle tone, feeding problems, and seizures. The disorder is autosomal recessive, which means a child gets one nonworking gene from each parent. NCBI+2MedlinePlus+2

Aminoacylase-2 deficiency”—better known in medicine as Canavan disease (ASPA deficiency). In genetics databases, the ASPA gene is also called ACY2 (aminoacylase-2), which is why some sources say “aminoacylase-2 deficiency.” Canavan disease is an inherited leukodystrophy in which the aspartoacylase (ASPA) enzyme is missing or very low. Without this enzyme, the brain can’t properly break down N-acetylaspartate (NAA), so NAA builds up and the supply of acetate for making myelin (the insulation around nerves) is reduced. This leads to poor myelin formation, enlarged head size in many infants, weak or stiff muscles, feeding problems, seizures, and developmental delay or regression. Diagnosis is confirmed by high NAA on urine testing or brain magnetic-resonance spectroscopy (MRS) and by finding two disease-causing ASPA variants on genetic testing. There is no approved cure yet; care focuses on seizures, nutrition, mobility, comfort, and family support, with gene-therapy trials in progress. NCBI+2NCBI+2

Other names

Doctors and books may use different names for the same condition. Other names include Canavan disease, Canavan–van Bogaert–Bertrand disease, aspartoacylase deficiency, ASPA deficiency, N-acetylaspartic aciduria, and aminoacylase-2 deficiency. All these names point to the same core problem: a lack of the aspartoacylase (aminoacylase-2) enzyme in the brain. Wikipedia+1

Types

Doctors describe two main clinical patterns. The first is the typical (infantile or neonatal) form. This is the most common and most severe. Babies look normal at birth, but by 3–5 months, parents notice poor head control, weak muscle tone, and very rapid head growth. Skills may not develop or may be lost. Seizures can appear. The second is a milder (juvenile/atypical) form. Children in this group may sit, walk, or talk to some degree. They still have learning and motor challenges, but the course is slower and often less severe. The differences come from how much enzyme activity remains and which mutations are present. NCBI+1

Causes

1. ASPA gene mutations (primary cause). Changes (variants) in the ASPA gene stop the enzyme from working. Without this enzyme, NAA cannot be broken down, and it builds up in the brain. MedlinePlus+1

2. Missense mutations. A single letter change in DNA can swap one amino acid for another in the enzyme, making it unstable or slow. Some missense variants leave a little activity, which can cause the milder form. MedlinePlus

3. Nonsense mutations. A mutation can create a “stop” signal too early. The shortened enzyme is nonfunctional, leading to the severe infantile disease. NCBI

4. Splice-site mutations. Changes at the borders of exons and introns can block correct RNA splicing, so the enzyme is mis-made or not made at all. NCBI

5. Frameshift or small insertions/deletions. These shift the reading frame and usually destroy enzyme function, producing severe disease. NCBI

6. Large deletions/duplications in ASPA. Losing or gaining bigger gene segments can wipe out enzyme production. Prevention Genetics

7. Founder mutations in specific populations. In people with Ashkenazi Jewish ancestry, two specific ASPA variants account for most cases, raising disease frequency in that group. MedlinePlus

8. Autosomal-recessive inheritance. A child is affected when both parents are carriers. Each pregnancy has a 25% chance of an affected child. Wikipedia

9. Carrier mating by chance. Even without family history, two carriers in any population can have an affected child, because ASPA variants occur worldwide. National Organization for Rare Disorders

10. Consanguinity (parents related by blood). When parents are related, they are more likely to carry the same rare variant, increasing risk for recessive diseases. National Organization for Rare Disorders

11. Protein misfolding of aspartoacylase. Some variants create an enzyme that folds poorly and gets degraded, lowering activity in the brain. ScienceDirect

12. Loss of enzyme stability at body temperature. Certain variants make the enzyme unstable, so it breaks down faster and cannot process NAA. ScienceDirect

13. Catalytic-site disruption. Mutations that change key amino acids at the active site directly block NAA hydrolysis. ScienceDirect

14. Defective oligodendrocyte ASPA. Aspartoacylase is made mostly in oligodendrocytes (the myelinating cells). If their ASPA is defective, myelin formation suffers. PMC

15. Toxic accumulation of NAA. Very high NAA alters brain water balance and myelin lipid production, leading to “spongy” degeneration of white matter. Eurorad+1

16. Shortage of brain acetate. ASPA normally provides acetate from NAA. Without it, the brain has less acetate for building myelin lipids. ScienceDirect

17. Impaired neuron-glia signaling. NAA is involved in neuron-glia metabolic exchange. Disrupted handling of NAA may stress both neurons and oligodendrocytes. ScienceDirect

18. Secondary white-matter injury pathways. Inflammation, oxidative stress, and edema can follow myelin failure and worsen damage. ScienceDirect

19. Delayed diagnosis. When the condition is not recognized early, supportive therapies are delayed, which can let complications (like aspiration or contractures) worsen outcomes. National Organization for Rare Disorders

20. Limited residual enzyme activity. The less activity remains, the earlier and more severe the disease appears; more residual activity often means a milder course. MedlinePlus

Symptoms

1. Macrocephaly (a large head). Many infants develop a rapidly growing head size in the first months of life. This is a key early clue. NCBI+1

2. Low muscle tone (hypotonia). Babies feel “floppy,” struggle with head control, and tire easily during handling or feeding. NCBI

3. Motor delay. Rolling, sitting, crawling, and walking are late or may not appear without significant support. NCBI

4. Developmental delay and regression. Some children gain skills and then lose them. Others never gain expected milestones. NCBI

5. Feeding problems. Weak suck, choking, reflux, and poor weight gain are common and may require feeding support. National Organization for Rare Disorders

6. Seizures. Many children develop seizures that need long-term treatment and monitoring. National Organization for Rare Disorders

7. Irritability or poor sleep. Brain discomfort, reflux, or seizures can disturb sleep and make babies fussy. National Organization for Rare Disorders

8. Abnormal muscle tone later (spasticity). Over time, stiffness can replace floppiness, especially in the legs. National Organization for Rare Disorders

9. Visual tracking problems or reduced vision. White-matter disease can affect pathways for seeing and tracking. National Organization for Rare Disorders

10. Strabismus (eye misalignment). Weak control of eye muscles can cause crossing or drifting of the eyes. National Organization for Rare Disorders

11. Poor head control and truncal weakness. The neck and trunk remain weak, making sitting and safe feeding harder. NCBI

12. Abnormal reflexes. Doctors may note brisk reflexes, clonus, or a Babinski sign as the disease progresses. NCBI

13. Breathing and swallowing issues. Coordination problems raise the risk of aspiration and pneumonia. National Organization for Rare Disorders

14. Failure to thrive. Due to feeding issues and high energy needs, some children do not gain weight or grow as expected. National Organization for Rare Disorders

15. Shortened lifespan in the severe form. Many children with the classic form develop life-threatening problems in childhood; milder forms can live much longer. National Organization for Rare Disorders+1

Diagnostic tests

Physical examination (bedside and clinical observations)

1. Growth and head measurements. Checking weight, length, and especially head size helps spot rapid head growth and failure to thrive. Large head size is a common early sign. NCBI

2. Neurologic exam of tone and reflexes. Doctors look for low tone in infancy, later stiffness, and abnormal reflexes that suggest white-matter disease. NCBI

3. Developmental screening. Simple tools and clinical observation measure delay in motor, language, and social skills to guide early therapies. National Organization for Rare Disorders

4. Vision and eye alignment exam. An ophthalmic check can find tracking problems or strabismus linked to brain white-matter changes. National Organization for Rare Disorders

5. Feeding and swallow assessment. Bedside feeding checks flag choking risk and the need for speech/swallow therapy or tube feeding. National Organization for Rare Disorders

Manual/bedside functional tests (simple clinical maneuvers)

6. Pull-to-sit test. The examiner gently pulls the baby by the arms to sit; poor head control suggests hypotonia. This is a quick, low-tech screen. NCBI

7. Vertical suspension. Holding the baby under the arms tests shoulder girdle tone; slipping through the hands suggests low tone. NCBI

8. Prone “head-lift” observation. Time spent lifting the head when lying on the belly shows neck and trunk strength delays. NCBI

9. Primitive reflex assessment. Persistence or absence of expected infant reflexes (e.g., Moro) can signal central nervous system problems. NCBI

Laboratory and pathological tests

10. Urine organic acids for NAA. A hallmark lab finding is very high N-acetylaspartic acid in urine. This is a key biochemical clue to Canavan disease. Eurorad+1

11. Plasma or CSF NAA. Blood or spinal fluid can also show elevated NAA, supporting the diagnosis, especially with MRI/MRS findings. Eurorad

12. ASPA enzyme activity (fibroblasts/leukocytes). Specialized labs can measure aspartoacylase activity; low or absent activity confirms the enzymatic defect. ScienceDirect

13. Molecular genetic testing of ASPA. Sequencing or a targeted variant panel finds the disease-causing variants. This is now the definitive test and also helps with family planning. NCBI+1

14. Carrier testing in parents. Once a child’s variants are known, parents can be tested to confirm carrier status and understand recurrence risk. Wikipedia

15. Prenatal or preimplantation testing (when desired). If family variants are known, testing during pregnancy or embryos can be offered by genetics teams. NCBI

Electrodiagnostic tests

16. EEG (electroencephalogram). EEG checks for seizure activity and helps choose anti-seizure medicines. Abnormal EEG is common in affected children with seizures. National Organization for Rare Disorders

17. Visual evoked potentials (VEP). VEP can detect delayed visual pathway responses caused by white-matter injury. National Organization for Rare Disorders

18. Brainstem auditory evoked responses (BAER). These can show slowed conduction in brainstem pathways when myelin is poor. National Organization for Rare Disorders

Imaging tests

19. Brain MRI. MRI usually shows widespread, symmetric changes in the white matter. The pattern fits a leukodystrophy with “spongy” degeneration. Eurorad

20. MR spectroscopy (MRS). MRS shows a very large NAA peak, which is highly suggestive of Canavan disease and supports the urine NAA finding. This is considered pathognomonic in the right clinical setting. Eurorad+1

Non-pharmacological treatments (therapies & other supports)

1. Early-intervention therapy (PT/OT/speech/feeding)
   A coordinated early-intervention program brings physical therapy (PT), occupational therapy (OT), speech-language and feeding therapy to the child and family. The aim is to build head control, improve posture, prevent contractures, support hand use, and strengthen safe swallowing. Therapists teach positioning, stretches, play-based movement, and communication strategies that fit daily routines. Early, frequent practice helps preserve abilities and comfort and reduces secondary complications such as aspiration, hip problems, and skin breakdown. Families also learn home programs and how to adapt toys and seating to the child’s needs. NCBI

2. Seizure action planning & caregiver training
   A simple written plan explains how to recognize a seizure type for that child, when to time it, when to use rescue medicine, and when to call emergency services. Training builds confidence for parents and school caregivers. The purpose is to shorten prolonged events, reduce injuries, and prevent emergency-department visits. Mechanistically, rapid, consistent responses reduce ongoing electrical storms in the brain and limit stress-related triggers. Plans also cover medication administration (e.g., rectal or intranasal benzodiazepines), positioning for safety, and post-seizure monitoring. NCBI

3. Feeding therapy & safe swallow strategies
   Speech-language pathologists assess sucking, chewing, and swallowing. They recommend textures (thicker liquids, purees), pacing, and positions that lower aspiration risk. The goal is safe nutrition and hydration without lung complications. Techniques such as chin-tuck, slow-flow nipples, and upright seating reduce airway entry; radiographic swallow studies are used when the signs are unclear to fine-tune textures and strategies. NCBI

4. Nutrition optimization & growth monitoring
   Registered dietitians build calorie-dense, frequent meals or tube-feeding plans. The purpose is to prevent malnutrition and support daily activity and immune function. Mechanistically, reliable energy supports muscle work and brain growth, and careful hydration helps prevent constipation and kidney stress. Regular tracking of weight/length and micronutrient status guides adjustments. NCBI

5. Gastrostomy tube (G-tube) support (non-drug care)
   For children with chronic choking, poor weight gain, or long feeds, teams teach families how to use and care for a G-tube. The purpose is safe, consistent nutrition and less stress at mealtimes. Mechanistically, bypassing unsafe oral phases reduces aspiration, dehydration, and hospitalization. Education covers pump use, venting for gas, skin care, and integrating oral tastes if safe. (The surgical insertion itself is covered under “Surgeries” below; this item focuses on the ongoing therapy and training.) NCBI

6. Positioning, adaptive seating, and mobility devices
   Custom seating, head supports, standers, and mobility aids prevent spine curvature, hip subluxation, and pressure injury, and they enable participation at home and school. The purpose is comfort, safety, and access to play and communication. Mechanistically, better alignment reduces abnormal muscle pull and pain, promoting easier breathing and feeding. NCBI

7. Range-of-motion and spasticity management (non-drug)
   Daily stretching, splinting, and gentle orthotic use keep joints flexible and delay contractures. The purpose is to maintain comfort and care ease (positioning, dressing, hygiene). Mechanistically, consistent low-load stretching opposes the stiffness that emerges as hypotonia evolves into spasticity with disease progression. NCBI

8. Respiratory physiotherapy & airway-care routines
   Chest physiotherapy, suctioning training, and cough-assist devices are taught when secretions or weak cough are issues. The aim is to prevent pneumonia and hospitalizations. These techniques help clear mucus, improve ventilation, and reduce work of breathing, especially during respiratory infections. NCBI

9. Vision assessment & habilitation
   Many children have reduced visual tracking or cortical visual impairment. Early ophthalmology review plus vision therapy and environmental adaptations (high-contrast objects, simplified backgrounds, controlled lighting) improve functional seeing and engagement. Mechanistically, repeated, structured visual experiences strengthen remaining pathways and help compensate for cortical processing limits. NCBI+1

10. Communication supports (AAC)
    When speech is limited, teams introduce augmentative and alternative communication (AAC)—from simple picture boards to eye-gaze devices. The purpose is to give the child a reliable voice for needs, comfort, and social interaction. Mechanistically, AAC reduces frustration, supports learning, and can coexist with any speech gains. NCBI

11. Education planning & inclusive activities
    Children benefit from individualized education plans with adapted materials, extra time, and assistive tech. Inclusive play (e.g., adaptive sports) builds social skills and quality of life. Regular developmental assessments guide goals and services across preschool and school years. NCBI

12. Orthopedic & seating clinics (non-operative care)
    Specialist clinics monitor hips, spine, and contractures and adjust braces, standers, and wheelchairs. The purpose is to detect problems early and preserve comfort and function. Mechanistically, timely orthotic tuning helps distribute pressure and reduces deformity progression, often delaying surgery. NCBI

13. Palliative-care partnership (alongside all other care)
    Palliative teams focus on comfort, symptom relief (pain, sleep disturbance, feeding stress), and family support from early in the journey. The aim is better day-to-day quality of life and coordinated care, not just end-of-life planning. Mechanistically, proactive symptom management can reduce hospitalizations and caregiver burnout. NCBI

14. Social work, respite, and community supports
    Families often need help with equipment funding, home nursing, transportation, and respite. Social workers connect families to benefits and reliable services, easing stress so caregivers can sustain care at home. Peer support groups also reduce isolation and share practical tips. NCBI

15. Sleep hygiene & routine-based care
    Regular bedtime routines, quiet environments, and optimized positioning can improve sleep quality. Better sleep helps daytime alertness, mood, and seizure threshold. Mechanistically, consistent cues and comfortable positioning decrease arousals and nighttime respiratory problems. NCBI

16. Infection-prevention practices
    Strict hand hygiene, up-to-date routine vaccines (per pediatric schedule), RSV-prevention when eligible, and early treatment plans for colds lower the odds of serious respiratory setbacks. Mechanistically, preventing infections reduces fever-related seizures and hospital stays. NCBI

17. Pain and tone-trigger management (non-drug)
    Identify and minimize pain triggers—reflux positions, constipation, pressure points, or ill-fitting braces. Gentle handling, heat, massage, and positioning changes can reduce discomfort and secondary spasticity surges. The purpose is calmer days and easier caregiving. NCBI

18. Regular neurologic & growth surveillance
    Scheduled reviews track head size, seizure control, breathing, nutrition, mobility, and safety of oral intake. The aim is early detection of new problems and timely adjustments in care plans. Mechanistically, proactive monitoring prevents crises and protects function. NCBI

19. Genetic counseling for the family
    Counselors explain inheritance (autosomal recessive), carrier testing for relatives, and options like prenatal or preimplantation testing in future pregnancies. The purpose is informed choices and early diagnosis in siblings if needed. NCBI

20. Clinical-trial participation (gene therapy & novel metabolic strategies)
    Families may be eligible for research studies, including ASPA gene-therapy programs (e.g., rAAV-Olig001-ASPA/MYR-101) and metabolic approaches (e.g., triheptanoin). The goal is to test disease-modifying strategies. Mechanistically, gene therapy aims to restore ASPA in oligodendrocytes and reduce CSF NAA while improving myelination; anaplerotic fuels aim to support brain energy pathways. Discuss risks and benefits with a specialist. PR Newswire+2Myrtelle, Inc.+2

---

Drug treatments

No drugs are FDA-approved specifically for Canavan disease; medicines below are used to manage symptoms such as seizures, spasticity, sialorrhea, reflux, pain, sleep, and nutrition. Doses must be individualized by your clinician, especially in infants/children with metabolic disorders. Always follow the current FDA label and your specialist’s advice.

1. Levetiracetam (e.g., Keppra/Spritam) — anti-seizure
   Class: Antiseizure medication (ASM).
   Typical dosing/timing (label): Pediatric dosing is weight-based; for oral solution/tablets, initial pediatric dosing often starts at 20 mg/kg/day divided twice daily and can be titrated (see label specifics by age and formulation). SPRITAM (orally disintegrating) is indicated for partial-onset seizures (≥4 years) and certain generalized seizures; Keppra XR is an extended-release option for adolescents/adults. Purpose/Mechanism: Reduces seizure frequency by modulating synaptic neurotransmitter release via SV2A binding. Key side effects: Somnolence, irritability/behavior change, dizziness; dose adjustments may be needed in renal impairment. FDA Access Data+1

2. Clobazam (Onfi/Sympazan) — adjunct for difficult seizures
   Class: Benzodiazepine (adjunctive ASM).
   Dosing (label): Weight-based; often 5 mg/day and titrated in divided doses; max varies by weight and response (see label tables). Purpose/Mechanism: Enhances GABA-A receptor activity to calm excessive neuronal firing, helpful when seizures remain despite other ASMs. Side effects: Sedation, drooling, constipation, behavioral changes; risk of dependence, withdrawal, and respiratory depression, especially with other CNS depressants (boxed warning class-wide). FDA Access Data

3. Midazolam nasal spray (Nayzilam) — rescue for seizure clusters
   Class: Benzodiazepine rescue therapy.
   Dosing (label): 5 mg intranasal in one nostril at onset; a second 5 mg dose may be given after 10 minutes if needed (age ≥12 y; see full label). Purpose/Mechanism: Rapid GABA-A enhancement aborts ongoing seizure clusters outside the hospital. Side effects: Somnolence, respiratory depression; ensure caregiver training and clear action plan. FDA Access Data+1

4. Diazepam rectal gel (Diastat) — home rescue for prolonged seizures
   Class: Benzodiazepine rescue therapy (C-IV).
   Dosing (label): Weight-based rectal dose for breakthrough seizures; may repeat once after 4–12 hours; do not exceed 5 episodes/month or 1 every 5 days. Purpose/Mechanism: Quickly stops prolonged seizures when IV access isn’t available. Side effects: Sedation, respiratory depression; ensure training and timing instructions. FDA Access Data+1

5. Baclofen — reduces spasticity
   Class: Antispasticity agent (GABA-B agonist).
   Dosing (label): Oral tablets; start low and titrate to effect; intrathecal baclofen pump is an option for severe spasticity (implant is surgical; see “Surgeries”). Purpose/Mechanism: Decreases excitatory neurotransmission in spinal cord to reduce muscle tone and spasms, easing care and comfort. Side effects: Sedation, weakness, hypotonia; taper slowly to avoid withdrawal. FDA Access Data

6. Tizanidine (Zanaflex) — alternative for spasticity
   Class: Central α2-adrenergic agonist.
   Dosing (label): Start low (e.g., 2 mg) and titrate; given up to three times daily; dose-dependent hypotension and sedation require cautious adjustments. Purpose/Mechanism: Presynaptic inhibition of motor neurons reduces spasticity and painful spasms. Side effects: Somnolence, dry mouth, hypotension, liver enzyme elevations (monitor). FDA Access Data

7. Glycopyrrolate oral solution (Cuvposa) — reduces drooling
   Class: Anticholinergic.
   Dosing (label/NDA review): Pediatric oral solution titrated to effect for chronic severe sialorrhea in neurologic conditions (ages ≥3 y in trials). Purpose/Mechanism: Blocks muscarinic receptors in salivary glands to lower saliva production, easing skin breakdown and aspiration risk. Side effects: Constipation, urinary retention, flushing, thickened secretions; monitor for overheating. FDA Access Data

8. IncobotulinumtoxinA (Xeomin) — injection for sialorrhea or spasticity
   Class: Botulinum toxin type A.
   Dosing (label): For adult chronic sialorrhea, 100 Units total divided into parotid/submandibular glands; pediatric dosing is weight-based with ultrasound guidance (see label). Purpose/Mechanism: Temporarily blocks acetylcholine release at salivary or neuromuscular junctions, reducing drooling or focal tone. Side effects: Local weakness, dry mouth, swallowing difficulty; boxed warning for distant toxin spread. FDA Access Data+1

9. Levocarnitine (Carnitor) — carnitine deficiency in inborn errors
   Class: Carnitine supplement (Rx).
   Dosing (label): Oral 330–990 mg per dose, 2–3×/day for deficiency; IV forms exist. Purpose/Mechanism: Replaces carnitine to support fatty-acid transport into mitochondria in secondary carnitine deficiency from inborn errors; used case-by-case in neurometabolic care. Side effects: GI upset (diarrhea), fishy odor. FDA Access Data+1

10. Valproic acid/divalproex — broad-spectrum ASM (use with caution)
    Class: Antiseizure medication (GABAergic, sodium-channel effects).
    Dosing (label): Weight-based, titrated to effect/levels; multiple oral forms. Purpose: Control generalized or mixed seizures. Mechanism: Increases GABA and modulates neuronal excitability. Cautions/side effects: Boxed warnings for hepatotoxicity, pancreatitis, and teratogenicity; monitor liver function and ammonia (hyperammonemia risk). In metabolic disorders, many specialists avoid or use with great caution. FDA Access Data+1

11. Midodrine/antireflux/constipation regimens (supportive meds)
    Class: Not disease-modifying; chosen per symptom. Purpose: Reduce reflux-related distress (e.g., proton-pump inhibitors), manage constipation (osmotic laxatives), or support orthostatic tolerance if needed. Mechanisms/side effects: Vary by agent; labels guide dosing and risks (e.g., PPIs—hypomagnesemia risk; laxatives—electrolyte shifts). These are individualized; consult your clinician and current FDA labels. (Representative labels used for dosing/safety in practice; no single drug is CD-specific.) — key CD care context from GeneReviews. NCBI

12. Triheptanoin (Dojolvi) — anaplerotic energy substrate (off-label in CD)
    Class: Medium-chain triglyceride (Rx; FDA-approved for LC-FAOD, not CD).
    Dosing (label for LC-FAOD): Start ~10% of daily caloric intake, titrate to ≤35% split ≥4 doses/day; given orally or by G-tube mixed with food/formula (follow label). Purpose/Mechanism: Provides C7 fatty acids that refill the Krebs cycle (anaplerosis) and may support brain energy; investigated in Canavan and other neurologic disorders but not approved for CD. Side effects: GI upset (abdominal pain, diarrhea), possible liver/lipid changes—monitor per label. FDA Access Data+1

Important: The antiseizure and antispasticity drugs above are used to control symptoms seen in Canavan disease, but they are not FDA-approved for Canavan disease itself. Dosing in infants and children with neurometabolic conditions must be individualized by specialists.

---

Dietary molecular supplements

(supportive; evidence varies—discuss with the treating team before use)

1. Triheptanoin (C7 triglyceride)
   A prescription, calorie-dense fat that feeds the Krebs cycle with propionyl-CoA and succinyl-CoA units. In metabolic/neurologic conditions it is studied to stabilize energy use and reduce breakthrough events; in Canavan, small studies and compassionate-use experiences have explored benefits, and animal models of CD show improved myelin markers and motor function with dietary triheptanoin. If prescribed, dosing follows the Dojolvi label (for LC-FAOD), titrated to tolerance, typically divided at least four times daily; monitor GI tolerance and labs. It is not an FDA-approved treatment for Canavan disease. FDA Access Data+2PubMed+2

2. Levocarnitine (L-carnitine)
   Carnitine ferries long-chain fatty acids into mitochondria. Some children with neurometabolic diseases develop secondary carnitine deficiency; replacing carnitine can improve energy handling and reduce fatigue. Dosing is individualized; prescription Carnitor tablets/solution are labeled for inborn-error-related carnitine deficiency, with typical oral doses around 50–100 mg/kg/day split 2–3 times (follow label and labs). Side effects are mostly GI (loose stools) and fishy odor; monitor for rare seizures in predisposed patients. FDA Access Data

3. Omega-3 fatty acids (DHA/EPA)
   Long-chain omega-3s are building blocks for neuronal membranes and may support synaptic function and anti-inflammatory pathways. While not specific to Canavan, they’re often considered to support general neurodevelopment and may aid vision function in cortical visual impairment contexts. Typical supplemental doses in pediatrics are modest and individualized; monitor for GI upset or bleeding risk at higher doses. Use as part of a nutrition plan, not as a stand-alone therapy. (General neurodevelopmental support; no FDA drug label exists for OTC fish oil supplements; clinical management anchored by GeneReviews’ supportive-care framework.) NCBI

4. Vitamin D
   Supports bone mineralization, muscle function, and immunity—important when mobility is limited and sunlight exposure is low. Serum 25-OH vitamin D should be checked; dosing then corrects deficiency per pediatric guidelines. Adequate vitamin D reduces fracture risk and supports comfort with positioning and standing programs. Monitor calcium and vitamin D levels to avoid excess. (Supportive care principle; not a CD-specific therapy.) NCBI

5. Calcium (if dietary intake is low)
   Ensures bone health, especially for children with reduced weight-bearing who are at risk for osteopenia. Dosing is age-based and adjusted for total dietary intake; excess can cause constipation or kidney stones. Use under dietitian/clinician guidance and pair with vitamin D. (Supportive care principle.) NCBI

6. Probiotics (GI comfort)
   Some children have reflux, constipation, or antibiotic-associated diarrhea. Certain probiotic strains can support stool regularity and reduce diarrheal episodes. Use pediatric-appropriate products, monitor tolerance, and avoid in severely immunocompromised states. Benefits are supportive, not disease-modifying. (Supportive care principle.) NCBI

7. Fiber supplements (e.g., partially hydrolyzed guar gum)
   Added soluble fiber can soften stools and ease constipation from immobility or anticholinergics (like glycopyrrolate). Introduce slowly with fluids to prevent gas and bloating. Aim is comfort and fewer ER visits for impaction. (Supportive care principle.) NCBI

8. Multivitamin/mineral supplementation
   Helps cover gaps when oral intake is limited or feeds are restricted. Choose pediatric-appropriate preparations; monitor iron status, B12, and folate based on labs. The goal is to support growth, immunity, and healing. (Supportive care principle.) NCBI

9. Sodium bicarbonate/citrate in selected metabolic settings
   When metabolic acidosis appears during intercurrent illness, clinicians may use alkalinizing agents. The aim is to maintain acid-base balance and comfort; dosing is individualized from standard pediatric guidance. This is not specific to Canavan and should be directed by the medical team. (Supportive metabolic care.) NCBI

10. Hydration & electrolyte solutions
    Oral rehydration solutions or adjusted tube-feed recipes help maintain hydration during illness or heat. Mechanistically, stable fluids and electrolytes support seizure threshold and reduce constipation. Use under clinician/dietitian guidance. (Supportive care principle.) NCBI

---

Immunity-booster / regenerative / stem-cell”-type therapies

(what’s real, what’s investigational; dosage/route where applicable; always specialist-led)

1. Gene therapy targeting ASPA (rAAV-Olig001-ASPA / MYR-101) — investigational
   What/Mechanism: Uses an adeno-associated virus (AAV) to deliver a working ASPA gene to oligodendrocytes, aiming to lower NAA and restore myelin lipid production. Dosing/route: Single-dose intrathecal/intracerebral administration within clinical trials. Function: Potential disease-modifying approach for children without approved treatments. Notes: Received FDA RMAT and inclusion in the FDA START pilot program; not yet approved. PR Newswire+1

2. Cell-based therapy using neural/oligodendrocyte progenitors — preclinical/early research
   What/Mechanism: Patient-derived or donor stem-cell–derived neural progenitors engineered to express functional ASPA, with the aim to repopulate myelinating cells. Dose/route: Investigational neurosurgical delivery in research settings. Function: Replace or support lost oligodendrocytes and improve myelination. Status: Experimental; not standard of care. ScienceDirect

3. Triheptanoin as an anaplerotic “metabolic support” — off-label
   What/Mechanism: Odd-chain triglyceride that supplies substrates to the Krebs cycle. Dose: Per Dojolvi label when prescribed for LC-FAOD (titrate to ≤35% of daily calories, ≥4 doses/day). Function: Aims to bolster brain energy and potentially support myelination/neuronal function; studied across neurometabolic disorders and models of CD. Side effects: GI upset; monitor labs. FDA Access Data+1

4. Botulinum toxin injections for spasticity & sialorrhea — symptomatic
   What/Mechanism: Local injections block acetylcholine release to reduce focal tone or saliva. Dose/route: Per label (e.g., Xeomin 100 Units total for adult sialorrhea; pediatric dosing weight-based). Function: Eases care, drooling-related skin issues, and discomfort. Risks: Local weakness, dysphagia; boxed warning for toxin spread. FDA Access Data

5. Intrathecal baclofen pump — symptomatic
   What/Mechanism: Surgically implanted pump infuses baclofen into CSF to reduce severe generalized spasticity when oral agents fail. Dose: Programmable continuous infusion; titrated by specialists. Function: Improves comfort, positioning, and caregiving. Risks: Catheter/pump complications; must avoid abrupt withdrawal. FDA Access Data

6. Comprehensive vaccination & infection-prevention measures — “immune support” in practice
   What/Mechanism: Up-to-date routine vaccines and prompt treatment of infections support the child’s immune resilience and reduce stressors that trigger seizures or hospitalizations. Dose/Timing: Per national pediatric schedules and clinician advice. Function: Prevention is the safest “immune boost” for medically fragile children. NCBI

---

Surgeries (what is done and why)

1. Gastrostomy tube (G-tube) placement
   Procedure: A small feeding tube is placed through the abdominal wall into the stomach (endoscopic or surgical).
   Why: For unsafe swallowing, poor growth, or exhausting mealtimes; it ensures reliable nutrition, hydration, and medication delivery and lowers aspiration risk. NCBI

2. Intrathecal baclofen pump implantation
   Procedure: A programmable pump is implanted under the skin with a catheter into the spinal canal.
   Why: To manage severe spasticity unresponsive to oral medicines, improving comfort, positioning, and caregiver ease. FDA Access Data

3. Orthopedic soft-tissue procedures (e.g., tendon releases)
   Procedure: Lengthening or releasing tight muscles/tendons to ease contractures.
   Why: Reduces pain, improves hygiene/positioning, and may delay scoliosis or hip subluxation progression in children with chronic tone abnormalities. NCBI

4. Hip stabilization surgery (for dysplasia/subluxation)
   Procedure: Guided-growth or reconstructive procedures to improve hip alignment.
   Why: Prevents pain and skin breakdown, supports sitting comfort, and simplifies care in children with spasticity-related hip problems. NCBI

5. Salivary-duct procedures (select cases)
   Procedure: Duct ligation or rerouting, occasionally gland excision, when conservative and injection therapies fail.
   Why: To reduce severe drooling that causes skin breakdown or aspiration risk, improving comfort and care. (Symptom-driven; specialist decision.) NCBI

---

Practical prevention strategies

1. Keep routine vaccines current and consider RSV prevention if eligible; infections can worsen breathing and seizures. NCBI

2. Build an early-response plan for fevers and colds (hydration, antipyretics per clinician advice, when to seek care). NCBI

3. Maintain seizure action plans and rescue-med training for all caregivers and schools. NCBI

4. Practice daily stretches and positioning to prevent contractures and pressure sores. NCBI

5. Use proper seating/standers to support spine and hips and reduce aspiration during feeds. NCBI

6. Monitor growth, hydration, and bowel habits; intervene early to avoid malnutrition or impaction. NCBI

7. Keep home suction and airway-clearance tools available if recommended; act early with secretions. NCBI

8. Optimize sleep hygiene to lower seizure risk and improve daytime function. NCBI

9. Ensure skin care around mouth (drooling) and pressure points; use barriers and frequent repositioning. NCBI

10. Pursue genetic counseling for family planning and early testing in siblings when appropriate. NCBI

---

When to see a doctor

See your child’s specialist promptly for new or worsening seizures, prolonged seizures (or clusters) that don’t stop with prescribed rescue medication, feeding difficulties (choking, coughing with feeds, weight loss), breathing problems (noisy breathing, repeated pneumonias), fever with lethargy, increasing stiffness or pain, rapid head growth in infancy, or any sudden regression of skills. Seek emergency care for any seizure lasting longer than the time in your action plan, blue lips/face, trouble breathing, or severe dehydration. Regularly scheduled visits with neurology, rehab/orthopedics, nutrition/feeding, and ophthalmology are recommended for surveillance and to adjust care early. NCBI

---

What to eat and what to avoid

Eat more of:

1. Calorie-dense formulas/foods to meet energy needs (dietitian-guided). NCBI

2. Texture-modified foods (purees/appropriate thickness) to protect the airway if advised by feeding therapy. NCBI

3. Hydration with oral rehydration solutions or scheduled G-tube water flushes. NCBI

4. Micronutrient-rich options (iron, B-vitamins, vitamin D, calcium) within a balanced plan. NCBI

5. Omega-3-containing foods (e.g., oily fish, fortified feeds) if appropriate. NCBI

Limit/avoid:

1. Thin liquids if the child aspirates—use thickened liquids when prescribed. NCBI
2. Hard, crumbly, or mixed-texture foods that raise choking risk without therapist clearance. NCBI
3. Excessive added sugars that displace needed protein/fats in limited volumes. NCBI
4. Dehydrating or constipating foods without counter-balancing fluids/fiber. NCBI
5. Unsupervised supplement use or off-label metabolic products without the team’s guidance. NCBI

---

Frequently asked questions

1. Is “aminoacylase-2 deficiency” the same as Canavan disease?
   Yes. Canavan disease is caused by ASPA (also known as ACY2) deficiency; many sources list “aminoacylase-2 deficiency” as a synonym. Orpha.net

2. What causes it?
   Two non-working ASPA gene copies (autosomal recessive inheritance). Parents are usually healthy carriers; each pregnancy has a 25% chance to be affected. NCBI

3. How is it diagnosed?
   By high NAA in urine or brain MRS and by finding biallelic ASPA variants on genetic testing. NCBI

4. What symptoms are common?
   Low muscle tone that later becomes stiffness, poor head control, enlarged head in many infants, feeding and swallowing problems, developmental delay/regression, and seizures; vision may be affected by cortical visual impairment or optic atrophy. NCBI

5. Is there a cure?
   Not yet. Current care is supportive (seizure control, nutrition, mobility, comfort). Gene-therapy trials are underway. NCBI+1

6. Why is N-acetylaspartate (NAA) important?
   Without ASPA, NAA builds up, and the brain may lack enough acetate to make myelin lipids; this is a central disease mechanism. PubMed

7. Do all children have seizures?
   Seizures are common and often increase over time; many need ongoing antiseizure therapy and rescue medicines. NCBI

8. Which anti-seizure drugs are used?
   Levetiracetam, benzodiazepines (clobazam, midazolam nasal spray for clusters, diazepam rectal gel for prolonged seizures), and others as guided by a neurologist; none are specifically approved for Canavan disease. Follow FDA labels for dosing and safety. FDA Access Data+3FDA Access Data+3FDA Access Data+3

9. Is valproic acid safe?
   It can help certain seizures but carries serious risks (liver toxicity, pancreatitis, hyperammonemia, teratogenicity). In neurometabolic disorders, clinicians often avoid or use it cautiously. FDA Access Data

10. Will a G-tube stop all feeding by mouth?
    Not necessarily. Many children keep tasting or taking small safe amounts orally while the G-tube ensures adequate calories and reduces aspiration risk. NCBI

11. What does palliative care mean here?
    An extra layer of support focused on comfort, symptom control, and family wellbeing, offered alongside all other treatments from early on. NCBI

12. How often should we see specialists?
    Regular, scheduled visits for neurology, rehab/orthopedics, feeding/nutrition, and ophthalmology are recommended to monitor growth, breathing, seizures, posture, and learning needs. NCBI

13. Are there reliable signs on MRI/MRS?
    Yes. Brain MRI shows a diffuse leukodystrophy pattern; MRS shows a high NAA peak, even when early MRI or urine NAA is not yet striking. NCBI+1

14. Is there hope from research?
    Yes. ASPA gene therapy (MYR-101/rAAV-Olig001-ASPA) has FDA RMAT and START designations, with early data showing CSF NAA reduction and myelin-volume signals; more trials are ongoing. PR Newswire+2Myrtelle, Inc.+2

15. What can families do right now?
    Focus on consistent routines, early therapies, seizure and feeding safety, infection prevention, and community supports. Ask about clinical-trial options with a metabolic or leukodystrophy center. NCBI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 09, 2025.

PDF Documents For This Disease Condition References